Evidence map›Paper›PMID 34270831›Full record

ArticleCancer science2021

Postoperative changes in plasma miR21-5p as a novel biomarker for colorectal cancer recurrence: A prospective study.

Masahiro Fukada, Nobuhisa Matsuhashi, Takao Takahashi, Nobuhiko Sugito, Kazuki Heishima, Kazuhiro Yoshida, Yukihiro Akao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Circulating MicroRNAs as Cancer Biomarkers in Liquid Biopsies.Advances in experimental medicine and biology · 2022
    Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Masahiro FukadaDepartment of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Japan.ORCID https://orcid.org/0000-0002-3263-1697
Nobuhisa MatsuhashiDepartment of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Japan.
Takao TakahashiDepartment of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Japan.
Nobuhiko SugitoUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.
Kazuki HeishimaUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.
Kazuhiro YoshidaDepartment of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Japan.
Yukihiro AkaoUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.ORCID https://orcid.org/0000-0001-8902-5367
Gifu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer-related microRNAs (miRNAs) are emerging as promising and noninvasive biomarkers for colorectal cancer (CRC). This study aimed to investigate the usefulness of postoperative changes in plasma miR21-5p levels for recurrence and progressive disease (PD) after surgical resection. This study was a prospective study of 103 CRC patients who underwent surgical resection. Self-paired plasma samples collected pre-operation (Pre), 7 days post-operation (POD7), 1 month post-operation (POM1), and 6 months post-operation (POM6) were analyzed. The miRNA levels were evaluated by quantitative reverse transcription PCR. Among the enrolled patients, ten cases (9.7%) of postoperative recurrence and six cases (5.8%) of postoperative PD occurred at POM6. In the recurrence and PD group, plasma miR21-5p levels significantly increased (POM1: P < .01, POM6: P < .01, respectively). The area under the curve (AUC) value for postoperative changes in plasma miR21-5p levels at POM1 and POM6 to discriminate recurrence and PD were 0.675 and 0.715, respectively. Combined analysis with postoperative carcinoembryonic antigen (CEA) level in discriminating recurrence and PD increased AUC values (POM1: 0.715 and POM6: 0.789). Furthermore, multivariate analysis for recurrence and PD after surgical resection showed that postoperative changes in the plasma miR21-5p level at POM1 and POM6 were independent prognostic factors (POM1: P = .03, POM6: P < .01). The postoperative changes in plasma miR21-5p level could be a useful noninvasive biomarker for monitoring and predicting recurrence and PD after surgical resection of CRC patients. Furthermore, plasma miR21-5p can predict recurrence and PD after surgical resection.

Indexed as

AdultAgedAged, 80 and overArea Under CurveBiomarkers, TumorCarcinoembryonic AntigenColorectal NeoplasmsDiagnosis, DifferentialDisease ProgressionFemaleHumansMaleMicroRNAsMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalBiomarkers, TumorCarcinoembryonic AntigenMicroRNAsMIRN21 microRNA, humanbiomarkercolorectal cancermicroRNAmiR21-5pprogressive diseaserecurrence

Identifiers

PMID34270831
PMCPMC8486189
OpenAlexW3177599511

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.